From:
`To:
`Cc:
`Subject:
`Date:
`Attachments:
`
`Dave Brown
`Alyson Berliner; James Major
`Robert Vitti
`Re: ARVO abstract
`Wednesday, March 3, 2010 12:45:07 PM
`DA VINCI Late Breaker ARVO abstract.pdf
`
`With the changes. Enjoy!
`
`Let me know if you see anything else.
`
`Dave
`
`On 3/3/10 12:21 PM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:
`
`Thanks, Dave!!
`
`Only two comments:
`Results: Anatomical effects (mean change in CRT) for each
`VTE arm ranged from -127μm to -195μm and were significantly greater than
`the mean change in CRT for the laser arm (-68μm; p<0.01).
`
`Conclusion: In this patient population at the 24-week primary endpoint,
`intravitreal VTE was generally well tolerated and produced significant
`improvements from baseline in visual acuity and retinal thickness, and a
`trend toward improvement in central retinal sensitivity as compared to laser
`photocoagulation.
`(To date, we do not have p values for retinal sensitivity. ?I will see if we can calculate them.
`?But for now, we should probably say there is a trend…)
`
`Let me know if you have any questions.
`
`Thanks!
`Alyson
`
`???????????????????????????????????????????????????????????????????????????????
`Alyson J Berliner, MD,PhD
`Director, Clinical Sciences, Ophthalmology
`Regeneron Pharmaceuticals
`(914) 785-3049 (office)
`(914) 815-8875 (mobile)
`(914) 593-1555 (fax)
`Alyson.Berliner@regeneron.com
`
`From: Dave Brown [mailto:dmbmd@houstonretina.com]
`Sent: Wednesday, March 03, 2010 12:51 PM
`To: Alyson Berliner; James Major
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2023 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`

`

`Cc: Robert Vitti
`Subject: Re: ARVO abstract
`
`Here is the submitted ARVO abstract-- Please proof to make sure I didn’t miss
`anything. We are fine on length.
`
`DMB
`
`On 3/2/10 7:09 PM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:
`
`Hi Dave,
`
`Here is the updated abstract with your edits, the endophthalmitis info, and some other
`tweaks to reduce the character count. When you submit, I do not think you will need the
`“Background” section. You are welcome to add part of this section to another section or
`leave it out, as space dictates. Please let me know if you have any additional
`questions/comments, or if you need any assistance in the submission. Also, can you let me
`know when the abstract has been submitted successfully?
`
`Thanks so much!
`Alyson
`
`This e-mail and any attachment hereto, is intended only for use by the addressee(s)
`named above and may contain legally privileged and/or confidential information. If you
`are not the intended recipient of this e-mail, any dissemination, distribution or copying
`of this email, or any attachment hereto, is strictly prohibited. If you receive this email in
`error please immediately notify me by return electronic mail and permanently delete
`this email and any attachment hereto, any copy of this e-mail and of any such
`attachment, and any printout thereof. Finally, please note that only authorized
`representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to
`enter into business dealings with any third party.
` This e-mail and any attachment hereto, is intended only for use by the addressee(s)
`named above and may contain legally privileged and/or confidential information. If you
`are not the intended recipient of this e-mail, any dissemination, distribution or copying
`of this email, or any attachment hereto, is strictly prohibited. If you receive this email in
`error please immediately notify me by return electronic mail and permanently delete
`this email and any attachment hereto, any copy of this e-mail and of any such
`attachment, and any printout thereof. Finally, please note that only authorized
`representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to
`enter into business dealings with any third party.
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2023 Page 2
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`